Relapse remains a major problem after a standard ASCT for MM. Strategies to prevent relapse have included post transplant maintenance therapy. M Coleman et al (
Disclosures: Thalidomide, biaxin and dexamethasone as maintenance therapy after ASCT for Multiple Myeloma.; Celgene provided financial support for the study.; Dr. Bensinger received honoraria from Celgene (less than $10,000 total).